NEI Research News

The National Eye Institute (NEI) recently launched the first-ever human gene therapy trial for the vision disorder X-linked retinoschisis (XLRS). Researchers are conducting the trial at the National Institutes of Health Clinical Research Center in...

In an NIH-supported clinical trial comparing three drugs for diabetic macular edema (DME), Eylea (aflibercept) provided greater visual improvement, on average, than did Avastin (bevacizumab) or Lucentis (ranibizumab) when vision was 20/50 or worse.

People are bad at staying focused. We’ve all had our minds wander when we try to concentrate on a task that requires paying close attention but isn’t all that engaging.

A class of medications long used to curb HIV infection shows promise as a therapy for age-related macular degeneration (AMD), suggest findings from an NIH-funded study.

For some people it feels like a speck of sand in the eye, or stinging or burning that doesn’t go away. For others, dry eye disease (or simply dry eye) can become a chronic condition that leads to blurred vision or even vision loss if it goes untreated.

Researchers at the National Institutes of Health have developed a technique that will speed up the production of stem-cell derived tissues.

Depression is a common risk for people who have lost their vision from age-related macular degeneration (AMD), but a new study shows that a type of rehabilitation therapy can cut this risk in half.

Telemedicine is an effective strategy to screen for the potentially blinding disease known as retinopathy of prematurity (ROP), according to a study funded by the National Eye Institute (NEI).

In laboratory tests, researchers have used electrical stimulation of retinal cells to produce the same patterns of activity that occur when the retina sees a moving object.

Researchers at the National Eye Institute (NEI) have described the functions of a gene responsible for anchoring cilia — sensory hair-like extensions present on almost every cell of the body.